NEO — NeoGenomics, Inc.
$17.99+4.17%
Last close: · regular session
Last 60 sessions
NEO closed at $17.99 (+4.17%) on Oct 28, 2026. Float: 125.9M shares. Latest SEC filing: 8-K on Oct 28, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NEO in the TickerWise workspace.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 2,200
- Website: https://www.neogenomics.com
Latest SEC filings for NEO
Latest NEO news
- NeoGenomics raises 2026 guidance to $807M-$809M while planning CEO transition in January 2027 Read article
- NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates Read article
- NeoGenomics expands Indica Labs partnership for precision oncology Read article
- NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026 Read article
- NeoGenomics down after leadership transition Read article
- What's Going On With NeoGenomics Stock Tuesday? Read article
- NeoGenomics (NASDAQ:NEO) Hits New 12-Month High After Analyst Upgrade Read article
- NeoGenomics taps Warren Stone as CEO; eyes $209M Q3 revenue Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.